Orforglipron — Investigational Oral GLP-1
Orforglipron is an investigational oral, non-peptide GLP-1 receptor agonist. Not FDA-approved; not commercially available.
Evidence-based answer
Orforglipron is an investigational oral, non-peptide GLP-1 receptor agonist. Not FDA-approved; not commercially available.
Regulatory status: Foundayo (orforglipron) received FDA approval on April 1, 2026 for chronic weight management in adults with obesity or certain adults with overweight. It is a once-daily oral small-molecule GLP-1 receptor agonist.
How it works
Unlike peptide GLP-1 medicines, orforglipron is a nonpeptide small molecule designed for oral absorption without the same fasting and water restrictions used by oral semaglutide.
Mechanism is context, not proof. A defensible claim requires human outcome data for the exact molecule, formulation, dose and population. Receptor activity alone cannot establish how much weight a patient will lose, whether an injury will heal or whether a compounded vial has the identity and potency of a trial product.
What the clinical evidence shows
In ATTAIN-1, the treatment-regimen estimand showed dose-dependent mean weight loss of approximately 7.5% to 11.2% at 72 weeks versus 2.1% with placebo. Results were lower than the mean reductions reported for high-dose injectable tirzepatide in separate studies, but cross-trial comparisons are not randomized head-to-head evidence.
| Study or evidence level | Population | Intervention | Main result | Interpretation |
|---|---|---|---|---|
| ATTAIN-1 | 3,127 adults without diabetes | Once-daily orforglipron, dose-ranging | −7.5% to −11.2% at 72 weeks | Placebo −2.1%; treatment-regimen estimand |
Clinical-use framework
Foundayo is taken once daily. Dose escalation and administration must follow the FDA-approved label; the exact cash price depends on strength and current program terms.
A safe plan includes medical history, medication reconciliation, pregnancy screening where relevant, contraindication review, a written titration or administration schedule, missed-dose instructions, side-effect escalation and follow-up. Laboratory testing is individualized; a universal panel is not evidence-based for every patient, but clinicians may order testing based on symptoms, comorbidities and the medicine considered.
How to evaluate an online program
- Identify the legal entities. The marketing company, prescribing practice and dispensing pharmacy may be different organizations.
- Confirm the clinician. Look for a full name, credential, NPI where applicable and authority to practice in the patient’s state.
- Read the prescription label. Verify the exact drug, salt or base, concentration, directions, facility and beyond-use date.
- Normalize cost. Add medication, membership, visits, labs, supplies, shipping and dose surcharges.
- Match the evidence. Ask whether the offered dose and route were studied for the claimed outcome.
- Review continuity. Understand refills, cold-chain handling, replacement, pharmacy changes and cancellation.
Safety
The FDA label carries a boxed warning about thyroid C-cell tumors observed in rodents. Gastrointestinal adverse effects are common, and treatment requires contraindication, interaction and monitoring review.
This page is educational and does not replace diagnosis or individualized prescribing. Severe symptoms, suspected overdose or a serious allergic reaction require urgent in-person evaluation.
Frequently asked questions
Is orforglipron (Foundayo) FDA approved?
Foundayo (orforglipron) received FDA approval on April 1, 2026 for chronic weight management in adults with obesity or certain adults with overweight. It is a once-daily oral small-molecule GLP-1 receptor agonist.
What is the strongest evidence for orforglipron (Foundayo)?
In ATTAIN-1, the treatment-regimen estimand showed dose-dependent mean weight loss of approximately 7.5% to 11.2% at 72 weeks versus 2.1% with placebo. Results were lower than the mean reductions reported for high-dose injectable tirzepatide in separate studies, but cross-trial comparisons are not randomized head-to-head evidence.
Can a compounded or microdose product claim the same trial result?
Not automatically. The trial result applies most directly to the studied product, dose, titration, population and duration. A different formulation, route or lower dose requires its own evidence.
What should be verified before treatment?
Verify the exact product, indication, prescriber, pharmacy, concentration, dose schedule, recurring cost, commitment, follow-up plan and urgent-care instructions.
Primary sources
- Foundayo FDA label Primary clinical or regulatory source
- FDA approval letter Primary clinical or regulatory source
- Foundayo official site Primary clinical or regulatory source
Provider marketing can document what is offered; it is not used as proof of safety or comparative effectiveness. Evidence was reviewed through July 12, 2026.